Cardiovascular morbidity in rheumatoid arthritis patients in North Canterbury, New Zealand 1999-2008

International Journal of Rheumatic Diseases

Volumn 16, Issue 1, 2013, Pages 19-23

  Khan, Emon A R ^a   Stamp, Lisa K ^b   O'Donnell, John L ^a   Chapman, Peter T ^a  

^a CANTERBURY DISTRICT HEALTH BOARD   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Cardiovascular disease; Rheumatoid arthritis

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DATA BASE; DEMOGRAPHY; FOLLOW UP; HUMAN; ICD-10; ICD-9; ISCHEMIC HEART DISEASE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MORBIDITY; NEW ZEALAND; OUTPATIENT CARE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

AGED; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMORBIDITY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEW ZEALAND; PREVALENCE; SURVIVAL RATE;

EID: 84874366378     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185x.12008     Document Type: Article

References (15)

1. Silman AJ, Hochberg MC (2001) Epidemiology of the rheumatic diseases, 2nd edn. Oxford University Press, Oxford.
2. Van Halm V, Peters M, Voskuyl A et al. (2009) Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis 68, 1395-400.
3. Choy E, Sattar N (2009) Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 68, 460-9.
4. Boers M, Nurmohamed M, Doelman C et al. (2003) Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 62, 842-5.
5. Greenberg J, Kremer J, Curtis J et al. (2011) Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 70, 576-82.
6. Munro R, Morrison E, McDonald A, Hunter J, Madhok R, Capell H (1997) Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis 56, 374-7.
7. Kitas G, Gabriel S (2011) Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 70, 8-14.
8. Sattar N, McCarey D, Capell H, McInnes I (2003) Explaining how "High-Grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108, 2957-63.
9. Snow M, Mikuls T (2005) Rheumatoid arthritis and cardiovascular disease: the role of systemic inflammation and evolving strategies of prevention. Curr Opin Rheum 17, 234-41.
10. Kaplan M (2006) Cardiovascular disease in rheumatoid arthritis. Curr Opin Rheum 18, 289-97.
11. Van Doornum S, McColl G, Wicks I (2004) Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann Rheum Dis 63, 1571-5.
12. McCarey D, McInnes I, Madhok R et al. (2004) Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363, 2015-21.
13. Stavropoulos-Kalinoglou A, Metsios G, Panoulas V et al. (2009) Associations of obesity with modifiable risk factors for the development of cardiovascular disease in patients with rheumatoid arthritis. Ann Rheum Dis 68, 242-5.
14. Dessein P, Joffe B, Veller M et al. (2005) Traditional and non-traditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 32, 435-42.
15. Bjornadal L, Brandt L, Klareskog L, Askling J (2006) Impact of parental history on patients' cardiovascular mortality in rheumatoid arthritis. Ann Rheum Dis 65, 741-5.